Metformin n = 52 | Placebo n = 51 | p value | |
---|---|---|---|
Primary outcome | |||
First 24 hours | n = 47a | n = 49a | |
Hyperglycemia episodesb | |||
Non GDM | 3.9 ± 1.4 | 4.0 ± 1.7 | 0.81 |
GDM | 3.9 ± 1.5 | 4.4 ± 1.6 | 0.40 |
Secondary outcomes | |||
First 24 hours | |||
Hypoglycemia episodesc | |||
Non GDM | 0.1 ± 0.2 | 0.2 ± 0.5 | 0.23 |
GDM | 0 ± 0 | 0.0 ± 0.0 | 0.48 |
Second 24 hours | n = 46a | n = 40a | |
Hyperglycemia episodesb | |||
Non GDM | 1.0 ± 1.3 | 1.1 ± 1.0 | 0.83 |
GDM | 1.5 ± 1.0 | 1.8 ± 1.2 | 0.70 |
Hypoglycemia episodesc | |||
Non GDM | 0.8 ± 0.9 | 0.6 ± 0.8 | 0.48 |
GDM | 0.4 ± 0.9 | 0.3 ± 0.6 | 0.27 |
Third 24 hours | n = 37a | n = 37a | |
Hyperglycemia episodesb | |||
Non GDM | 0.5 ± 1.0 | 0.6 ± 0.8 | 0.94 |
GDM | 0.3 ± 0.7 | 0.7 ± 1.1 | 0.61 |
Hypoglycemia episodesc | |||
Non GDM | 0.7 ± 0.9 | 0.8 ± 0.8 | 0.37 |
vGDM | 0.9 ± 0.8 | 1.1 ± 0.9 | 0.43 |
Blood sugar profile points 4–9 | |||
Hyperglycemic episodes | 2.7 ± 1.5 | 3.1 ± 1.4 | 0.16 |
3 [2-4] | 3 [2-4] | 0.15 |